Search results
Results from the WOW.Com Content Network
The Merck Manuals (outside the U.S. and Canada: The MSD Manuals; Chinese: 默沙东诊疗手册; pinyin: Mòshādōng Zhěnliáo Shǒucè) are medical references published by the American pharmaceutical company Merck & Co. (known as MSD outside the United States and Canada), that cover a wide range of medical topics, including disorders, tests, diagnoses, and drugs.
Elbasvir/grazoprevir, sold under the brand name Zepatier, is a fixed-dose combination for the treatment of hepatitis C, containing elbasvir (an inhibitor of hepatitis C virus's NS5A protein) and grazoprevir (an NS3/4A inhibitor). It is used to treat chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in both treatment-naïve and ...
The first edition of The Merck Manual was published in 1899 by Merck & Co., Inc. for physicians and pharmacists and was titled Merck's Manual of the Materia Medica. [6] [7] The 192 page book which sold for US $1.00, was divided into three sections, Part I ("Materia Medica") was an alphabetical listing of all known compounds thought to be of therapeutic value with uses and doses; Part II ...
“Hepatitis C is a blood-borne virus,” says Dr. Dieterich. “It is transmitted through the blood, so IV drug use is a major driver of the virus, especially now due to the heroin epidemic.
The Merck Veterinary Manual is a reference manual of animal health care. It was first published by Merck & Co., Inc. in 1955. [1] It contains concise, thorough information on the diagnosis and treatment of disease in a wide variety of species. [2] The Manual is available as a book, published on a non-profit basis. [3]
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. [2] [3] It binds to the HCV nonstructural protein 3 active site. [4] It was initially developed by Schering-Plough, [5] then by Merck after it acquired Schering in 2009.
Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of hepatitis C.It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. As of 2019 it was in Phase III human clinical trials.
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; [2] it is a type of viral hepatitis. [6] During the initial infection period, people often have mild or no symptoms. [1] Early symptoms can include fever, dark urine, abdominal pain, and yellow tinged skin. [1]